The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

Boston Scientific Corp. last week announced that it has closed on its acquisition of Irvine-based medical device maker ...

Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Travis Steed ...

for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented at ...

On Friday, Boston Scientific Corporation (BSX) stock saw a decline, ending the day at $86.99 which represents a decrease of $-0.60 or -0.69% from the prior close of $87.59. The stock opened at $87.12 ...

Marie Thibault, an analyst from BTIG, maintained the Buy rating on Boston Scientific (BSX – Research Report). The associated price target ...

Boston Scientific (NYSE:BSX) stock climbed 5% Monday after the medical device maker announced a study has shown its Watchman ...

Boston Scientific (NYSE:BSX) announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX ...

Boston Scientific announced the acquisition in January, but the review timeline dragged on after the Federal Trade Commission ...

Axonics (NASDAQ:AXNX) quickly edged higher by 0.8% after a Nasdaq delisting notice for its planned sale to Boston Scientific ...

Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).